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Improvement in cardiovascular biomarkers
sustained at 4 years following an initial treat-to-
target strategy in early rheumatoid arthritis
Rheumatology key message
. Initial treat-to-target therapy in early rheumatoid
arthritis has sustained cardiovascular risk benefits
at 4 years.
SIR. It is well recognized that individuals with RA are at
greater risk of cardiovascular disease (CVD), with EULAR
guidance advising optimal control of disease activity to
reduce this risk [1]. The cardiovascular substudy of the
Infliximab as Induction Therapy in Early Rheumatoid
Arthritis (IDEA) trial evaluated infliximab (IFX) + MTX vs
MTX + methylprednisolone (MP) (n= 38 and 41 in each
group, respectively) using a treat-to-target approach in
early RA and reported improvements in soluble cardio-
vascular biomarkers in both groups at week 78, with a
greater improvement in insulin resistance in the
IFX + MTX group [2, 3]. At week 78 the patients were
discharged back to routine clinical care. Four years
after their initial baseline IDEA visit, they were invited to
participate in a follow-up study (IACON REC 09/H1307/
98) to determine any long-term cardiovascular benefits
of treat-to-target management and to evaluate for differ-
ences between the initial IFX + MTX and MTX + MP treat-
ment arms.
Following obtaining informed consent, patients were
assessed for RA disease activity and medication use
and any new diagnosis of ischaemic heart disease (IHD),
cerebrovascular accidents (CVAs), peripheral arterial dis-
ease (PAD), hypertension, hypercholesterolaemia or dia-
betes mellitus (following medical notes review/patient
questioning). Mirroring our previous IDEA substudy,
blood samples were taken to quantify three commonly
measured soluble cardiovascular biomarkers: N-terminal
pro-brain natriuretic peptide (NT-proBNP), homeostasis
model assessmentestimated insulin resistance (HOMA-
IR) and total cholesterol/high-density lipoprotein choles-
terol (TC/HDL-C).
Eighteen patients were lost to follow-up between week
78 and year 4 (IFX + MTX, n= 10; MTX + MP, n= 8); follow-
up data were available for 28 in the IFX + MTX group and
33 in the MTX + MP group. Comparing IFX + MTX vs
MTX + MP at the baseline visit of the IDEA study, 64 vs
70% were female, 54 vs 64% were RF positive and 63 vs
78% were ACPA positive, respectively.
At year 4, of those initially in the IFX + MTX group, the
three-variable 28-joint DAS (DAS28) was 1.80 (95% CI
1.10, 2.50), none were receiving oral steroids, 75% were
receiving conventional synthetic DMARDs (csDMARDs;
61% MTX monotherapy) alone and 25% were receiving
biologic DMARDs [bDMARDs; 18% TNF inhibitor (TNFi)
therapy; 12% IFX], compared with those initially in the
MTX + MP group, where the three-variable DAS28 was
1.9 (95% CI 1.1, 2.35), 9% were receiving oral prednisol-
one (median dose 5 mg), 73% were receiving csDMARDs
(36% MTX monotherapy) alone and 18% were receiving
bDMARDs (15% TNFi therapy, 12% IFX).
Since week 78, there were five new diagnoses of car-
diovascular disease (IFX + MTX: 2 IHD, 1 CVA; MTX + MP:
1 IHD, 1 PAD), no new diagnoses of diabetes mellitus
and seven new diagnoses of hypercholesterolaemia
(IFX + MTX, n= 4; MTX + MP, n= 3). One (4%) of the
IFX + MTX cohort received a new diagnosis of hyperten-
sion compared with six (18%) of the MTX + MP cohort
(P= 0.225).
Soluble biomarker data were available for 40 patients
(IFX + MTX, n= 20; MTX + MP, n= 20). Results at weeks 26
and 78 were comparable to those of the original IDEA
cardiovascular substudy [2]. Continued improvements in
soluble biomarkers of cardiovascular risk 4 years from
baseline were shown regardless of the drug regimen
(see Table 1); NT-proBNP values were 5369% of base-
line, HOMA-IR were 4557% of baseline and TC/HDL-C
decreased by 1.281.61. There were no significant differ-
ences observed between the treatment groups at year 4.
While the difference in the incidence of new hyperten-
sion did not reach statistical significance, and notably
some patients in the MTX + MP group were taking oral
prednisolone at year 4, it may be clinically important.
While glucocorticoids have a known association with
hypertensive disease [4], IFX has been linked with
reduced systolic blood pressure in patients with RA. In a
trial of 16 RA patients, new IFX exposure was associated
with a reduction in systolic blood pressure, along with re-
ductions in plasma norepinephrine and renin activity [5].
This could suggest that the mechanism extends beyond
that of simply reducing disease activity and inflammation.
Our cross-sectional analysis may also suggest that the
initial beneficial impact of IFX + MTX on insulin resistance
shown at week 78 had been lost by 4 years. However, the
findings are limited by the small sample size and cross-
sectional nature of the analysis, with a lack of knowledge
about fluctuating disease activity/inflammation over the
last 30 months—a known confounder of HOMA-IR [6]. In
addition to patients receiving oral steroids at year 4 in the
MTX + MP group, not all patients remained on IFX after
week 78 in the alternative arm. Perhaps, for sustained in-
sulin resistance improvement, continuous exposure to the
drug is required.
To conclude, we report an intensive 78 week treat-to-
target programme in early RA is associated with sustained
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long-term benefit in the improvement of soluble bio-
markers of CVD, suggesting the potential for a reduction
of cardiovascular risk in the long term.
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TABLE 1 Changes to biomarker and lipoprotein values over time, separated by treatment regimen
Change in variable MTX + MP IFX + MTX
Unadjusted difference
(95% CI), P-value
Adjusted difference (95% CI),
P-valueb
Week 26
NT-proBNP mean
ratio
0.88 (n=30) 0.95 (n=26)
(0.96)a
1.09 (0.77, 1.54), 0.636c
1.10 (0.77, 1.57), 0.610a,c
1.11 (0.78, 1.59), 0.548c
1.14 (0.80, 1.61), 0.456a,c
HOMA-IR mean
ratio
0.67 (n=30)
(0.74)a
0.67 (n=25) 1.00 (0.57, 1.77), 0.990c
0.91 (0.53, 1.56), 0.725a,c
0.77 (0.50, 1.20), 0.244c
0.74 (0.50, 1.11), 0.145a,c
TC/HDL-C mean 0.64 (n=30) 0.82 (n=26) 0.18 (0.88, 0.52), 0.619 0.21 (0.78, 0.37), 0.472
Week 78
NT-proBNP mean
ratio
0.79 (n=30) 0.91 (n=22)
(0.91)a
1.15 (0.75, 1.77), 0.517c
1.14 (0.74, 1.79), 0.529a,c
1.17 (0.76, 1.82), 0.473c
1.13 (0.75, 1.72), 0.550a,c
HOMA-IR mean
ratio
0.81 (n=30)
(0.89)a
0.66 (n=22) 0.81 (0.44, 1.51), 0.506c
0.74 (0.41, 1.33), 0.303a,c
0.64 (0.39, 1.06), 0.08c
0.62 (0.38, 0.098), 0.042a,c
TC/HDL-C mean 0.94 (n=29) 1.13 (n=21) 0.19 (1.08, 0.69), 0.663 0.12 (0.75, 0.51), 0.701
Year 4
NT-proBNP mean
ratio
0.53 (n=20) 0.69 (n=20)
(0.69)a
1.31 (0.74, 2.31), 0.342c
1.32 (0.73, 2.36), 0.346a,c
1.32 (0.73, 2.37), 0.350c
1. 31 (0.72, 2.38), 0.368a,c
HOMA-IR mean
ratio
0.45 (n=20)
(0.52)a
0.57 (n=20) 1.26 (0.67, 2.37), 0.471c
1.09 (0.61, 1.95), 0.765a,c
0.91 (0.58, 1.44), 0.679c
0.83 (0.59, 1.17), 0.272a,c
TC/HDL-C mean 1.28 (n=20) 1.61 (n=20) 0.33 (1.45, 0.78), 0.551 0.47(1.061, 0.122), 0.116
HDL-C mean
(S.D.), (mg/dl)
11.6 (14.0) (n=20) 18.0 (11.7) (n=20) 6.4 (1.8, 14.7), 0.125 6.8 (1.2, 14.7), 0.093
LDL-C mean
(S.D.), (mg/dl)
22.2 (28.2) (n=20) 5.9 (41.5) (n=20) 16.3 (39.0, 6.4), 0.155 12.3 (31.0, 6.4), 0.190
ApoA mean (S.D.),
(g/l)
0.025 (0.365)
(n=20)
0.018 (0.192)
(n=20)
0.007 (0.180, 0.193), 0.944 0.032 (0.131, 0.195), 0.694
ApoB mean (S.D.),
(g/l)
0.255 (0.159)
(n=20)
0.187 (0.251) (n=20) 0.069 (0.204, 0.067),
0.310
0.062 (0.188, 0.063),
0.320
LpA, geometric
mean, (g/l)
0.889 (n=16) 0.938 (n=15) 1.05 (0.72, 1.55), 0.777c 1.03 (0.69, 1.53), 0.887c
aMinus extreme outlier. bAdjusted for baseline values. cValues exponentiated to give the ratio of the difference of one group vs
another with associated CIs. *P< 0.05. ApoA: apolipoprotein A; ApoB: apolipoprotein B; LDL: low-density lipoprotein choles-
terol; LpA: lipoprotein A.
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Long-term preservation of measles and rubella
specific-IgG antibodies in children with enthesitis
related arthritis on anti-TNFa treatment:
a prospective controlled study
Rheumatology key message
. Enthesitis related arthritis children on antiTNFa
show accelerated measles and rubella antibody
loss while retaining satisfactory seroprotection.
SIR, Immunization in patients with rheumatic disease is es-
sential, as they are at risk for infection due to the immuno-
suppressive effect of both the disease and its treatment.
Data regarding response and long-term immunological
memory to specific vaccines are lacking. At present, we
are experiencing major measles outbreaks throughout
Europe. Measles infection is associated with potentially
serious complications [1] as well as sustained immune-
memory loss predisposing patients to bacterial/
opportunistic infections [2]. On the other hand, rubella
infection in pregnant women is linked to serious neonatal
consequences [1].
In this study we aimed to determine the immune status
against measles and rubella in previously vaccinated
enthesitis related arthritis (ERA) patients, prior to the com-
mencement of biologic (anti-TNFa) treatment and at one
and three years later and compare these findings to
healthy controls. Secondary outcomes were to assess if
additional treatment would further interfere with seropro-
tection rates and antibody status.
This was a prospective, controlled study held at P. & A.
Kyriakou Children’s Hospital over a period of six years.
Forty-one ERA patients fulfilling the ILAR JIA classification
criteria [3] and 149 controls were included. All participants
had received two doses of MMR vaccine at 2 and 5 years
of age. Blood sampling was performed prior to initiation of
anti-TNFa treatment and at specific intervals afterwards
(0, 12, 36 months). In the majority of patients, biologic and
synthetic DMARDs were initiated simultaneously following
failure of NSAID treatment. Mean time from diagnosis to
anti-TNFa treatment was 9.4 months; mean duration of
treatment was 3.4 years. Seroprotection rates as well as
measles and rubella-IgG titres were measured; titres were
assessed by ELISA and were expressed as geometric
mean concentrations (GMCs). Commercial EIA kits for de-
tection of antibodies against MMR (Dade-Behring,
Germany) were used. The cut-off value for seroprotection
was deemed at 120 IU/ml (measles) and 10 IU/ml (rubella),
based on international standards [4]. Total IgG levels were
measured simultaneously.
All participants were included and sampled between
November 2011 and July 2018. The study was performed
in compliance with the Declaration of Helsinki. The
Hospital’s Research and Ethics’ Committee approved
the study (Approval number 19/2045/1108-2011); in-
formed consent was obtained. Statistical significance
was set at P < 0.05 and analyses were conducted using
STATA (version 13.0).
ERA patients were less up to date with their vaccin-
ations (P = 0.02). Seroprotection rates were adequate
for both the ERA and the control group. Nonetheless,
the ERA group had consistently, but not statistically sig-
nificant, lower rates. Mean measles-IgG antibodies (as
well as GMCs) were significantly lower in the ERA com-
pared with the control group (P < 0.05) at 1 and 3 years’
follow-up, but not at diagnosis. The same was also evi-
dent for rubella to a more pronounced degree (P < 0.01)
(Table 1). None of the participants had hypogammaglobu-
linaemia at the time of blood sampling. None of the par-
ticipants were infected by rubella or measles during the
study period. During the follow-up period, the ERA group
had greater decrease in antibody levels as indicated from
the significant interaction effect of analysis (both measles
and rubella). Subgroup analysis showed that age, gender,
time interval between the two doses of the vaccine as well
as time lapse from last MMR vaccination to initiation of
treatment did not affect either rubella or measles-specific-
IgG concentrations. Intermittent systemic corticosteroid
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